GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biocytogen Pharmaceuticals (Beijing) Co Ltd (HKSE:02315) » Definitions » Quick Ratio

Biocytogen Pharmaceuticals (Beijing) Co (HKSE:02315) Quick Ratio : 1.10 (As of Dec. 2023)


View and export this data going back to 2022. Start your Free Trial

What is Biocytogen Pharmaceuticals (Beijing) Co Quick Ratio?

The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. It is calculated as a company's Total Current Assets excludes Total Inventories divides by its Total Current Liabilities. Biocytogen Pharmaceuticals (Beijing) Co's quick ratio for the quarter that ended in Dec. 2023 was 1.10.

Biocytogen Pharmaceuticals (Beijing) Co has a quick ratio of 1.10. It generally indicates good short-term financial strength.

The historical rank and industry rank for Biocytogen Pharmaceuticals (Beijing) Co's Quick Ratio or its related term are showing as below:

HKSE:02315' s Quick Ratio Range Over the Past 10 Years
Min: 1.1   Med: 1.57   Max: 3.31
Current: 1.1

During the past 4 years, Biocytogen Pharmaceuticals (Beijing) Co's highest Quick Ratio was 3.31. The lowest was 1.10. And the median was 1.57.

HKSE:02315's Quick Ratio is ranked worse than
78.83% of 1545 companies
in the Biotechnology industry
Industry Median: 3.6 vs HKSE:02315: 1.10

Biocytogen Pharmaceuticals (Beijing) Co Quick Ratio Historical Data

The historical data trend for Biocytogen Pharmaceuticals (Beijing) Co's Quick Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biocytogen Pharmaceuticals (Beijing) Co Quick Ratio Chart

Biocytogen Pharmaceuticals (Beijing) Co Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Quick Ratio
3.31 1.77 1.36 1.10

Biocytogen Pharmaceuticals (Beijing) Co Semi-Annual Data
Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Quick Ratio Get a 7-Day Free Trial 1.77 1.07 1.36 1.16 1.10

Competitive Comparison of Biocytogen Pharmaceuticals (Beijing) Co's Quick Ratio

For the Biotechnology subindustry, Biocytogen Pharmaceuticals (Beijing) Co's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biocytogen Pharmaceuticals (Beijing) Co's Quick Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Biocytogen Pharmaceuticals (Beijing) Co's Quick Ratio distribution charts can be found below:

* The bar in red indicates where Biocytogen Pharmaceuticals (Beijing) Co's Quick Ratio falls into.



Biocytogen Pharmaceuticals (Beijing) Co Quick Ratio Calculation

The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.

Biocytogen Pharmaceuticals (Beijing) Co's Quick Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Quick Ratio (A: Dec. 2023 )=(Total Current Assets-Total Inventories)/Total Current Liabilities
=(790.857-97.491)/631.784
=1.10

Biocytogen Pharmaceuticals (Beijing) Co's Quick Ratio for the quarter that ended in Dec. 2023 is calculated as

Quick Ratio (Q: Dec. 2023 )=(Total Current Assets-Total Inventories)/Total Current Liabilities
=(790.857-97.491)/631.784
=1.10

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Biocytogen Pharmaceuticals (Beijing) Co  (HKSE:02315) Quick Ratio Explanation

The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.

In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.

The higher the quick ratio, the better the company's liquidity position.


Biocytogen Pharmaceuticals (Beijing) Co Quick Ratio Related Terms

Thank you for viewing the detailed overview of Biocytogen Pharmaceuticals (Beijing) Co's Quick Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Biocytogen Pharmaceuticals (Beijing) Co (HKSE:02315) Business Description

Traded in Other Exchanges
Address
12 Baoshen South Street, Daxing Bio-Medicine Industry Park, Daxing District, Beijing, CHN
Biocytogen Pharmaceuticals (Beijing) Co Ltd is a biopharmaceutical and pre-clinical research services company. It has two Core Products, YH003 and YH001. YH003 is a recombinant humanized agonistic anti-Cluster of Differentiation 40 (CD40) Immunoglobulin G2 (IgG2) monoclonal antibody and YH001 is a recombinant humanized anti-CTLA-4, a protein receptor expressed constitutively on T cells that functions as an immune checkpoint and downregulates immune responses, Immunoglobulin G1 (IgG1) monoclonal antibody. YH003 is being developed for pancreatic ductal adenocarcinoma, melanoma and other advanced solid tumors. YH001 is being developed for hepatocellular carcinoma (HCC), non-small-cell lung carcinoma (NSCLC) and other solid tumors.
Executives
Bvcf Realization Fund, L.p. 2201 Interest of corporation controlled by you
Zhao Yin Guo Ji Jin Rong You Xian Gong Si 2201 Interest of corporation controlled by you
Zhao Yin Guo Ji Jin Rong Kong Gu You Xian Gong Si 2201 Interest of corporation controlled by you
Prowell Ventures Pte Ltd 2201 Interest of corporation controlled by you
Gic Special Investments Private Limited 2102 Investment manager
Gic Private Limited 2201 Interest of corporation controlled by you
Gic (ventures) Pte. Ltd. 2201 Interest of corporation controlled by you
Yang Zhi 2201 Interest of corporation controlled by you
Innoveda Medtech, Ltd. 2201 Interest of corporation controlled by you
Ni Jian
Bvcf Realization Fund Gp, Ltd. 2201 Interest of corporation controlled by you
Bioveda China Fund Ii Rmb, Limited 2101 Beneficial owner
Cmbi Private Equity Series Spc 2201 Interest of corporation controlled by you
Cmb International Private Investment Limited 2201 Interest of corporation controlled by you
Cmb International Investment Management Limited 2201 Interest of corporation controlled by you

Biocytogen Pharmaceuticals (Beijing) Co (HKSE:02315) Headlines

No Headlines